Base editing technology invented at Rutgers, The State University of New Jersey, and exclusively licensed to Revvity, Inc. subsidiary Horizon Discovery, has been sub-licensed to biopharmaceutical company AstraZeneca to support its creation of cell therapies for the treatment of cancer and immune-mediated diseases.
Rutgers is part of a new federally funded regional collaboration to drive economic and technological advancements in photonics, the National Science Foundation (NSF) announced. The consortium, which includes researchers from Rutgers-Newark and Rutgers-New Brunswick, awarded a development grant from the NSF’s Regional Innovation Economic Engine consortium, led by Princeton University and co-led by Rowan University, with partners throughout New Jersey and neighboring states Delaware, Pennsylvania and New York.
In an effort to expand and enhance New Jersey’s research and innovation ecosystem, Rutgers Office for Research’s Innovation Ventures will participate in a technology transfer partnership with the New Jersey Association of State Colleges and Universities (NJASCU).
Rutgers, The State University of New Jersey, has earned prestigious accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for the first time. Through this coveted certification, Rutgers Human Research Protection Program (HRPP) and Institutional Review Board (IRB) join the elite ranks of University Human Research Protection programs.
As the United States and the world continue to battle COVID-19 and other zoonotic diseases, a group of scientists and experts from New Jersey, Delaware, Pennsylvania, Maryland, West Virginia and Virginia will convene for a Regional One Health Consortium Conference at Rutgers University. Participants will consist of scientists who will share data and expertise on how to address a variety of topics and diseases affecting the health of humans, animals and the environment across the region, including ticks and tick-borne diseases, mosquitoes, rabies, and bird flu.
Rutgers researcher, Grace Brannigan, has co-authored a study published in The Proceedings of the National Academy of Sciences (PNAS) that centers around the connection between gene mutations in protein sequences and diseases.
A Rutgers researcher will use genomics, genetics, and cell biology to identify and understand the corals’ response to heat stress conditions and to pinpoint master regulatory genes involved in coral bleaching due to global warming and climate change. The researcher and his team will use a novel gene-editing tool as a resource to knock down some gene functions with the goal of boosting the corals’ abilities to survive.
The Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB), headquartered at the Rutgers Institute for Quantitative Biomedicine, announces the expansion of its data storage capacity through the Amazon Web Services (AWS) Open Data Sponsorship Program. The AWS program is providing the RCSB PDB with more than 100 terabytes of storage for no-cost delivery of Protein Data Bank information to millions of scientists, educators, and students around the world working in fundamental biology, biomedicine, bioenergy, and bioengineering/biotechnology.
A pair of Rutgers researchers are teaming up to combat climate change and worldwide hunger at the same time. Yong Mao, associate research professor and lead biologist in the Laboratory for Biomaterials Science at Rutgers School of Arts and Sciences, and Joseph Freeman, professor, director of the Musculoskeletal Regeneration Laboratory, and graduate program director of biomedical engineering in Rutgers School of Engineering, will collaborate with Atelier Meats, a biotechnology company, to develop and produce lab-grown, structured meats.
In a landmark genetic study of more than 121,000 people, an international consortium called SCHizophrenia Exome Meta-Analysis (SCHEMA), led by researchers at the Broad Institute of MIT and Harvard, has identified extremely rare protein-disrupting mutations in 10 genes that strongly increase an individual's risk of developing schizophrenia. The Genomic Psychiatry Cohort (GPC) study, based at Rutgers, The State University of New Jersey and led by Drs. Carlos and Michele Pato, is a major contributor to this study and the second, complementary study, led by researchers at Cardiff University on behalf of the Psychiatric Genomics Consortium (PGC).
A Rutgers researcher’s new formula with Investigational New Drug (IND) status has successfully alleviated a patient’s long-term severe gastrointestinal (GI) illness associated with post-acute COVID-19 syndrome, or long-haul COVID, in a recent study. The study’s results on the formula developed by Liping Zhao, Ph.D., are now published in an article titled “Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post-Acute COVID-19 Syndrome” in mBio, a peer-reviewed journal of the American Society for Microbiology.
The Center for Tobacco Studies at Rutgers, The State University of New Jersey received a $2.6 million grant from the National Cancer Institute (NCI) to evaluate cigarette relighting – the practice of smoking a cigarette, extinguishing it, and lighting it again to smoke – as well as its consequences on health and efforts to quit smoking.
A Rutgers professor’s novel research into targeting and silencing defective, disease-causing RNA molecules has led to the launch of Ceptur Therapeutics, a startup that has raised $75 million in Series A funding. The initial research that led to the creation of Ceptur was conducted by principal investigator Samuel I. Gunderson, PhD, associate professor of molecular biology and biochemistry at Rutgers-New Brunswick’s School of Arts and Sciences. Gunderson’s research focused on Ribonucleic acid (RNA), specifically how to manipulate and control RNA to understand its functions and treat different genetic diseases, such as certain blood cancers and neurological disorders.
Rutgers, The State University of New Jersey joins the ranks of 53 premier international institutions from 12 countries invited to participate in the Novartis Institutes for BioMedical Research (NIBR) Global Scholars Program (NGSP). The competitive program is designed to support innovative thinkers from select academic institutions in translating their breakthrough science into transformative medicine and/or clinical research to improve the lives of patients.
A novel medical device that works as an absorbable implant for meniscal reconstruction, invented by researchers at Rutgers, The State University of New Jersey, received the 2021 Thomas Edison Patent Award in the Biotechnology category. The tissue-engineered implant treats meniscal tears to lessen or even entirely rid the need for a total knee replacement surgery. The implant also recreates the anatomy and fiber geometry of the meniscus.
The wind energy industry could soon count on a much-needed precise analysis to achieve an optimal balance for wind farm productivity and profitability, thanks to a team of researchers working with digitization, predictive and prescriptive analytics to bring down its operational costs.
Asthma and allergies are chronic health conditions that continue to adversely impact the quality of life for many around the world. Thanks to exciting breakthroughs by Mark Siracusa, a researcher at Rutgers, The State University of New Jersey, there may be early signs of light at the end of the tunnel.
Advancing its mission and leadership role to improve climate risk management critical to societal well-being, Rutgers, The State University of New Jersey will lead a multi-university Megalopolitan Coastal Transformation Hub (MACH) made possible by a grant through the National Science Foundation’s Coastlines and People (CoPe) Program with expected total funding of $19.9+ million over the next five years.
As a key player in developing and transforming innovators into entrepreneurs that improve people’s lives, Rutgers, The State University of New Jersey will expand its entrepreneurship training programming and further equip faculty and student researchers with the skills and strategy needed to transition their discoveries into technologies and products, as a partner in the newly created NSF I-Corps™ Hub: Northeast Region.
Jason H. Yang, Ph.D., chancellor scholar and assistant professor of Microbiology, Biochemistry and Molecular Genetics in the Center for Emerging and Re-Emerging Pathogens at Rutgers New Jersey Medical School (NJMS), has been awarded the 2021 Agilent Early Career Professor Award
The National Science Foundation (NSF) announced today that it has awarded a coalition of academic and oceanographic research organizations a five-year, $220 million contract to operate and maintain the Ocean Observatories Initiative (OOI). The coalition, led by the Woods Hole Oceanographic Institution (WHOI), with direction from the NSF and guidance from the OOI Facilities Board, will include the University of Washington (UW), Oregon State University (OSU), and Rutgers University.
Rutgers University’s TechAdvance Fund, a proof-of-concept fund created through the university’s Office of Research and Economic Development (ORED) to advance early stage Rutgers technologies toward commercialization, received $100,000 from Celgene Corporation, marking the first corporate donation since the program’s inception in June 2017.
Dr. Joachim Kohn, Director of New Jersey Center for Biomaterials and Board of Governors Professor of Chemistry at Rutgers, The State University of New Jersey, received the Innovation Hero award for his pioneering research achievements at this year’s Healthcare Heroes event which recognizes individuals and organizations that are making a significant impact on the quality of healthcare in New Jersey.
A breakthrough patent – the polymer that enabled the development of the world’s first fully resorbable and x-ray visible coronary stent – invented by a Rutgers University researcher received the 2017 Edison Patent Award from the Research & Development Council of New Jersey. The award memorializes the state’s most prolific inventor, Thomas Alva Edison, and highlights the Garden State’s continuous pipeline of exceptional innovation work.
Jeetendra (Jeetu) Eswaraka, DVM, Ph.D., DACLAM, who joined Rutgers University’s Office of Research and Economic Development earlier this month as Assistant Vice President for Comparative Medicine Resources, brings a decade and a half of experience leading lab animal research programs in the biopharmaceutical industry.
Under the leadership of Rutgers University-New Brunswick scientist Dr. Joachim Kohn, a civilian research program established by the U.S. Department of Defense to focus on regenerative medicine for the treatment of battlefield injuries has made great strides that culminated in a total face transplant performed at the Cleveland Clinic in May.
Rutgers University ranks 21st among the Top 100 Worldwide Universities Granted U.S. Utility Patents in 2016, according to a new report published by the National Academy of Inventors and Intellectual Property Owners Association.
Rutgers University has licensed a technology that allows for the mass production of high-quality graphene at a reduced cost to Everpower International Holdings Co., Ltd. (“Everpower”).
Richard Riman, distinguished professor of materials science and engineering at Rutgers, has been elected as a Fellow of the National Academy of Inventors. He holds more than 10 U.S. patents and patents pending for the “low-temperature solidification” process he invented.
RTMDx, a program developed by criminologists Joel Caplan and Leslie Kennedy at Rutgers University–Newark, is now being licensed to SUNY Cortland for classroom use.
Rutgers and Thermo Fisher Scientific have collaborated to foster Rutgers’ research on continuous manufacturing techniques for pharmaceutical discovery. With support from Thermo Fisher, C-SOPS has obtained a twin screw extruder/granulator, which will be used for testing of extrusion and granulation processes in continuous manufacturing.
Rutgers is receiving a $4 million NSF grant to create and assess a regional computing infrastructure for collaborative data-intensive science. The team includes faculty at the Rutgers Discovery Informatics Institute, Penn State University, City University of New York, Drexel and Temple.
A team at the Rutgers has won a $300,000 contract with the CDC to investigate emergence of antifungal drug resistance by the common fungal pathogen Candida glabrata. Fungal infections are a leading cause of morbidity and mortality among individuals with compromised immune systems. Treatment options are already highly limited.
Two new companies from Rutgers presented Sept. 20 at University Startup Demo Day in the U.S. Capitol Building. Celvive is refining a stem-cell technology for regenerative medicine use such as spinal cord injury. XPEED Turbine Technology is developing aerodynamic technology for wind energy production.
Heagele, a doctoral student in the Rutgers School of Nursing, discusses why you and your family likely aren't prepared for a natural disaster in your area.
The Target ALS Foundation has selected RUCDR Infinite Biologics to bank and distribute its human stem cell lines for use by ALS researchers in academia and industry worldwide.
Rutgers new supercomputer, “Caliburn,” was rated by Top 500 as #8 most powerful system among U.S. academic institutions, and #2 among Big Ten Universities.
The Ocean Observatories Initiative's data center, which collects and shares data from more than 800 instruments and a transmission network across the Atlantic and Pacific, is operating at Rutgers. The university has an initial $11.8 million contract to design, build and operate the OOI cyberinfrastructure.
BioMotiv has created a biotech startup, Z53 Therapeutics, to discover and develop new agents for the treatment of p53-dependent cancers using a technology from Rutgers University. The company has licensed IP around the discovery of small molecules that act as zinc metallochaperones to shuttle zinc across cell membranes and reactivate mutant p53.
Visikol Inc., a student-run biotech startup from Rutgers that markets a technology platform for use in scientific and medical research, has earned a $500,000 commitment from a venture capital group. Visikol sells a versatile clearing agent, which is a chemical formula that renders tissues transparent, allowing researchers to effectively visualize biological tissues in 3-D, as opposed to traditional slicing based 2-D visualization.
The National Institute of Neurological Disorders and Stroke has awarded a five-year grant worth up to $6 million to RUCDR Infinite Biologics, a unit of Rutgers. The world’s largest university-based biorepository, RUCDR will manage the NINDS stem cell repository and will provide a comprehensive range of stem-cell related services.
The FDA has awarded $4.9 million in funding to a consortium based at the Rutgers University to support the introduction of continuous manufacturing techniques for pharmaceuticals. The grants, administered by the NIH, will increase research and development efforts for continuous manufacturing, a major innovation in the industry, over 3 years.
Rutgers is launching a new Business Portal, a website designed to serve the region’s corporate community. It offers users easy access to four key areas—research, technology licensing, professional development and recruiting—and provides two internal search functions and clear pathways to units at Rutgers such as corporate engagement and translational sciences.
A new stent for cardiovascular disease made from a polymer invented at Rutgers has been implanted in patients for the first time. The drug-eluting stent is made from a tyrosine-based polymer that is visible using X-ray, aiding cardiologists implanting the device. The polymer also is fully bioresorbable.
Richard Riman will join the N.J. Inventors Hall of Fame Oct. 16. A graduate of MIT and Rutgers, he is being honored for his process that captures and sequesters carbon in concrete products. He holds 10 U.S. patents for his low-temperature solidification process now being commercialized by a company he founded, Solidia Technologies.
RUCDR Infinite Biologics, a unit of Rutgers’ Human Genetics Institute of New Jersey, expanding its focus from genomic research to the rapidly growing field of clinical genomics. The world’s largest university-based biorepository, RUCDR earned its initial CLIA certification from the federal government, which is a key step.
Susan Dolbert, a fundraiser with experience in health care practice, research and education, has been named vice president of development for Rutgers Biomedical and Health Sciences (RBHS). She will join the the Rutgers University Foundation on Sept. 2.
The National Institute on Drug Abuse has given a contract worth up to $19 million to RUCDR Infinite Biologics, part of Rutgers’ Human Genetics Institute. The world’s largest university-based biorepository, RUCDR will enhance the services of its NIDA Center for Genetic Studies, which provides genomic services to NIDA-funded researchers.
Rutgers School of Criminal Justice app maps high-risk locations
Three Rutgers faculty members have been named fellows of the National Academy of Inventors: Joachim Kohn and Kathryn Uhrich, professors in Chemistry and Chemical Biology, and Richard Mammone, professor of engineering and business. The academy’s 2013 fellows, announced Dec. 10, include 143 inventors. Among them are nine Nobel Laureates.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right